122 related articles for article (PubMed ID: 9704186)
1. A patient with breast cancer and paraneoplastic cerebellar syndrome associated with anti-Purkinje cell antibodies: response to CMF chemotherapy.
Faris M; Abraham J; Barrett-Lee P
Clin Oncol (R Coll Radiol); 1998; 10(3):202-3. PubMed ID: 9704186
[TBL] [Abstract][Full Text] [Related]
2. [Reversible paraneoplastic cerebellar symptoms. An example of anti-Ri syndrome].
Pfeiffer G; Grupp C
Nervenarzt; 1998 Jun; 69(6):516-8. PubMed ID: 9673976
[TBL] [Abstract][Full Text] [Related]
3. Cerebellar ataxia as a paraneoplastic syndrome.
Dropcho EJ; Whitaker JN
Hosp Pract (Off Ed); 1989 Jan; 24(1A):69-79, 83-4. PubMed ID: 2536377
[No Abstract] [Full Text] [Related]
4. Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study.
Cocconi G; Bisagni G; Bella M; Acito L; Anastasi P; Carpi A; Di Costanzo F; Frassoldati A; Mosconi A; Borrini A; Buzzi P
Am J Clin Oncol; 1999 Dec; 22(6):593-600. PubMed ID: 10597744
[TBL] [Abstract][Full Text] [Related]
5. Selective concentration of anti-Purkinje cell antibody in the CSF of two patients with paraneoplastic cerebellar degeneration.
Graus F; Segurado OG; Tolosa E
Acta Neurol Scand; 1988 Sep; 78(3):210-3. PubMed ID: 3227806
[TBL] [Abstract][Full Text] [Related]
6. Phase III randomized comparison of postoperative adjuvant chemotherapy with 2-year oral uracil/tegafur versus 6-cycle cyclophosphamide/methotrexate/5-fluorouracil in high-risk node-negative breast cancer patients.
Watanabe T
Cancer Chemother Pharmacol; 1998; 42 Suppl():S68-70. PubMed ID: 9750032
[TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced breast cancer: How much chemotherapy is enough?
DiPaola RS; Kaufman A; Mikhail MM
Semin Oncol; 1996 Jun; 23(3):xv-xxii; discussion xxii-xxiv. PubMed ID: 8658211
[No Abstract] [Full Text] [Related]
8. [Paraneoplastic cerebellar degeneration: case report of a patient with breast carcinoma].
Huober J; Niedermaier N; Drlicek M; Kaufmann M; Hacke W; Bastert G
Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):214-6. PubMed ID: 8682288
[TBL] [Abstract][Full Text] [Related]
9. Paraneoplastic opsoclonus and cerebellar ataxia related to anti-Ma2 antibody: a case report.
Mélé N; Hautefort C; Toledano A; Delattre JY; Psimaras D
J Neurol; 2016 Feb; 263(2):405-406. PubMed ID: 26754007
[No Abstract] [Full Text] [Related]
10. Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration.
Furneaux HM; Rosenblum MK; Dalmau J; Wong E; Woodruff P; Graus F; Posner JB
N Engl J Med; 1990 Jun; 322(26):1844-51. PubMed ID: 2348838
[TBL] [Abstract][Full Text] [Related]
11. Anti-Ri-associated paraneoplastic ophthalmoplegia-ataxia syndrome in a woman with breast cancer: a case report and review of the literature.
Sena G; Gallo G; Vescio G; Gambardella D; de Franciscis S; Renne M
J Med Case Rep; 2020 Jun; 14(1):67. PubMed ID: 32527295
[TBL] [Abstract][Full Text] [Related]
12. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
[TBL] [Abstract][Full Text] [Related]
13. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer.
Ejlertsen B; Mouridsen HT; Jensen MB; Bengtsson NO; Bergh J; Cold S; Edlund P; Ewertz M; de Graaf PW; Kamby C; Nielsen DL
J Clin Oncol; 2006 Nov; 24(31):4956-62. PubMed ID: 17075113
[TBL] [Abstract][Full Text] [Related]
14. [Subacute cutaneous lupus erythematosus and cancer: two cases and literature review].
Gantzer A; Regnier S; Cosnes A; Ortonne N; Wolkenstein P; Bagot M; Duong TA
Ann Dermatol Venereol; 2011 May; 138(5):409-17. PubMed ID: 21570567
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
Ost E; Illiger HJ
Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
[No Abstract] [Full Text] [Related]
16. Anti-Purkinje cells antibodies in two cases of paraneoplastic cerebellar degeneration.
Sindic CJ; Andersson M; Boucquey D; Chalon MP; Bisteau M; Brucher JM; Laterre EC
Acta Neurol Belg; 1993; 93(2):65-77. PubMed ID: 8506746
[TBL] [Abstract][Full Text] [Related]
17. [A case of paraneoplastic cerebellar degeneration--success in early detection of cancer by anti-Purkinje cell antibody].
Igarashi S; Tanaka K; Nakajima T; Yamazaki M; Inuzuka T; Miyatake T
Rinsho Shinkeigaku; 1992 Mar; 32(3):309-13. PubMed ID: 1628454
[TBL] [Abstract][Full Text] [Related]
18. [Subacute paraneoplastic cerebellar degeneration with anti-neuronal antibodies and gynecological cancers. A case report of a bilateral ovarian cancer where the classic "anti-YO" antibody is associated with another antineuronal antibody].
Tremouilhac C; Hamy A; De Ferron E; Paineau J; Visset J
J Gynecol Obstet Biol Reprod (Paris); 1996; 25(3):253-6. PubMed ID: 8767221
[TBL] [Abstract][Full Text] [Related]
19. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 1. Mouse strains bearing different MHC molecules produce antibodies on immunization with recombinant Yo protein, but do not cause Purkinje cell loss.
Tanaka M; Tanaka K; Onodera O; Tsuji S
Clin Neurol Neurosurg; 1995 Feb; 97(1):95-100. PubMed ID: 7788981
[TBL] [Abstract][Full Text] [Related]
20. [61-year-old patient with rapidly progressive cerebellar symptoms].
Becker K; Wurster U; Kienast K; Fischer B
Pneumologie; 1995 Dec; 49(12):700-3. PubMed ID: 8584543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
